Sax Wealth Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Sax Wealth Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$203K	Buy	+2,310	New	+$240K	0.01%	705

Other funds holding DNTH

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

QP Wealth Management Eatontown, New Jersey $66.5M AUM 63.94% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Eagle Bay Advisors New York $137M AUM 18.51% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Private Trust Company Cleveland, Ohio $1.27B AUM 20.99% 1-Year Est. Return

Grove Bank & Trust Miami, Florida $1.01B AUM 19.76% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

Sax Wealth Advisors's DNTH Position: Q3 2026 in Review

Sax Wealth Advisors opened a new position in Dianthus Therapeutics (DNTH) in Q3 2026: 2,310 shares worth $203K. The stake represents 0.01% of the portfolio and ranks #705 among its holdings.

18 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

Sax Wealth Advisors held 2,310 shares of Dianthus Therapeutics worth $203K as of Q3 2026.
Dianthus Therapeutics was a new Sax Wealth Advisors position in Q3 2026.
Dianthus Therapeutics made up 0.01% of Sax Wealth Advisors's portfolio in Q3 2026, its #705 holding.
18 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Sax Wealth Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.